Indication
B-cell malignancies, autoimmune diseases.
Product schedules
Phase I dose-escalation trial in lymphoma completed, well-tolerated in lymphoma patients; efficacy demonstrated in relapse and resistant lymphoma patients.
Phase I/II clinical study for relapsed/refractory primary immune thrombocytopenia (ITP) has shown significant efficacy and well tolerated with favorable safety profile.
Planned initiation of a clinical study for Primary Sjögren's Syndrome (pSS).
Molecular characteristics
Targets a specific B-cell surface marker highly expressed on various malignant B-cells and autoimmune B cells.
Blocks the BAFF/BAFF-R signaling pathway.
ESG206 demonstrated monotherapy efficacy in patients with relapsed/refractory lymphoma who had received multiple prior lines of therapy (including CD20 antibodies) and induced significant shrinkage of intracranial metastatic lesions.
In the primary immune thrombocytopenia trial, ESG206 rapidly increased platelet counts in subset patients.
ESG206 has shown a favorable safety profile across clinical trials for multiple indications, with a low incidence and mild severity of adverse events (such as infections).
